Volume 12, Issue 3, Pages (September 2005)

Slides:



Advertisements
Similar presentations
Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?
Advertisements

Neonatal Oxygen Increases Sensitivity to Influenza A Virus Infection in Adult Mice by Suppressing Epithelial Expression of Ear1  Michael A. O'Reilly,
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Ashley L Cooney, Brajesh K Singh, Patrick L Sinn  Molecular Therapy 
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Volume 12, Issue 1, Pages (July 2005)
Evolving Gene Therapy in Primary Immunodeficiency
FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B
Liposome Enhances CRAd Therapy
Requirements for allergen-induced airway inflammation and hyperreactivity in CD4- deficient and CD4-sufficient HLA-DQ transgenic mice  Svetlana P. Chapoval,
Volume 25, Issue 6, Pages (June 2017)
Volume 12, Issue 5, Pages (November 2005)
John R. Martin, Christopher E. Nelson, Mukesh K
Volume 8, Issue 3, Pages (September 2003)
Volume 26, Issue 2, Pages (February 2018)
Volume 25, Issue 1, Pages 5-7 (January 2017)
Volume 6, Issue 3, Pages (September 2002)
Volume 14, Issue 1, Pages (July 2006)
Volume 9, Issue 4, Pages (April 2004)
Use of Perfluorochemical Liquid Allows Earlier Detection of Gene Expression and Use of Less Vector in Normal Lung and Enhances Gene Expression in Acutely.
Volume 6, Issue 2, Pages (August 2002)
Volume 18, Issue 6, Pages (June 2010)
Volume 9, Issue 4, Pages (April 2004)
Volume 14, Issue 3, Pages (September 2006)
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 9, Pages (September 2010)
Lentivirus-Mediated Gene Transfer to Human Epidermis
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
Volume 21, Issue 4, Pages (April 2013)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Strong Promoters Are the Key to Highly Efficient, Noninflammatory and Noncytotoxic Adenoviral-Mediated Transgene Delivery into the Brain in Vivo  Christian.
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Donna M. Martin, Yehoash Raphael  Molecular Therapy 
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain  Cassia N. Cearley, John.
Volume 17, Issue 2, Pages (February 2009)
Volume 12, Issue 4, Pages (October 2005)
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Plasmid Delivery in Vivo from Porous Tissue-Engineering Scaffolds: Transgene Expression and Cellular Transfection  Jae-Hyung Jang, Christopher B. Rives,
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Volume 17, Issue 12, Pages (December 2009)
Volume 10, Issue 4, Pages (October 2004)
Molecular Therapy - Methods & Clinical Development
Volume 12, Issue 2, Pages (August 2005)
Volume 13, Issue 3, Pages (March 2006)
Volume 13, Issue 1, Pages (January 2006)
Volume 26, Issue 2, Pages (February 2018)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Volume 18, Issue 6, Pages (June 2010)
Maria P Limberis, Christie L Bell, Jack Heath, James M Wilson 
Volume 20, Issue 9, Pages (September 2012)
MicroRNA-21 and the Vulnerability of Atherosclerotic Plaques
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Volume 14, Issue 3, Pages (September 2006)
Volume 6, Issue 5, Pages (November 2002)
Therapeutic Efficacy of G207, a Conditionally Replicating Herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters  Kenji.
MRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma  Yuhua Wang, Lu Zhang, Zhenghong.
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Tatiana Zavorotinskaya, Adrian Tomkinson, John E Murphy 
Volume 11, Issue 1, Pages (January 2005)
Development of Novel Formulations That Enhance Adenoviral-Mediated Gene Expression in the Lung in Vitro and in Vivo  Maria A. Croyle, Xuan Cheng, Arbans.
Volume 3, Issue 1, Pages 8-13 (January 2001)
Volume 11, Issue 2, Pages (February 2005)
Volume 3, Issue 5, Pages (May 2001)
Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter  Lawrence E Ostrowski, James R Hutchins,
Presentation transcript:

Volume 12, Issue 3, Pages 502-509 (September 2005) Targeting Viral-Mediated Transduction to the Lung Airway Epithelium with the Anti- inflammatory Cationic Lipid Dexamethasone–Spermine  Amber Price, Maria Limberis, Jeffrey A. Gruneich, James M. Wilson, Scott L. Diamond  Molecular Therapy  Volume 12, Issue 3, Pages 502-509 (September 2005) DOI: 10.1016/j.ymthe.2005.03.033 Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 1 (A, C, E, G, I, J) Cryosections of lung at day 1 and (B, D, F, H) day 7 post-instillation of the AdV vector (2.5 × 1011 GC) stained for AlkP (A, B, E, F, I) and adjacent sections counterstained with H&E (C, D, G, H, J). DS/DOPE targeted expression to the airways (A, B), whereas AdV vector alone resulted in uniform transgene expression (E, F). PBS controls showed no AlkP expression (I). H&E staining demonstrated that AdV formulated with DS/DOPE (C, D) resulted in low cellular infiltration, similar to that in the PBS control (J), while AdV vector delivery alone resulted in a high cellular infiltration (G, H). Molecular Therapy 2005 12, 502-509DOI: (10.1016/j.ymthe.2005.03.033) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 2 (A, B) Histochemical staining for LacZ gene expression and (C, D) adjacent sections counterstained with H&E at day 1 post-instillation of liposome-formulated AdV-LacZ vector (1011 GC). Both DS/DOPE and DC-Chol/DOPE formulations resulted in airway epithelial cell targeting, but DS/DOPE formulation (A, C) exhibited less cellular infiltration compared to the DC-Chol/DOPE formulation (B, D). (E, G, I) CD8+ T cells at days 1 and (F, H, J) 7 post-instillation of 1011 GC of AdV vector. CD8+ T cells are present when AdV was delivered alone (E, F) but not when AdV was formulated with DS/DOPE (G, H) or in PBS controls (I, J). Molecular Therapy 2005 12, 502-509DOI: (10.1016/j.ymthe.2005.03.033) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 3 (A–D) LacZ gene expression in mouse lung at day 7 for AdV vector (1011 GC) or (E–H) day 21 for AAV vector (1011 GC). Vector was delivered alone (A, E) or with DS/DOPE (B, F), DC-Chol/DOPE (C, G), or dexamethasone (D, H). Expression was targeted to airway epithelial cells with DS/DOPE and DC-Chol/DOPE formulations, but not with vector formulated with dexamethasone or delivered alone. Molecular Therapy 2005 12, 502-509DOI: (10.1016/j.ymthe.2005.03.033) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 4 LacZ gene expression in A549 and MDCK cells. (A) In A549 cells transduced with an m.o.i. of 10/cell AdV vector formulated with 300 μl of 0.5 mM lipid or dexamethasone, LacZ gene expression was highly enhanced only in the DS/DOPE group, (B) while at an m.o.i. of 104/cell the expression was similar for all vector coformulations. (C) In MDCK cells, AdV vector (m.o.i. of 104/cell) was formulated with 300 μl of lipid or dexamethasone (concentrations as indicated). DS/DOPE significantly increased transgene expression at 100 μM lipid concentration and DC-Chol/DOPE also increased LacZ gene expression, though to a lesser extent than DS/DOPE. Dexamethasone did not increase expression compared to AdV vector delivered. Molecular Therapy 2005 12, 502-509DOI: (10.1016/j.ymthe.2005.03.033) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions